Patent US5045312A successfully refreshed from Google Patents.
US5045312A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Physiologically active compositions of growth hormone and serum albumin or Ig G
Assignee: Mallinckrodt Veterinary Inc
•
Filing: 1988-10-27
•
Granted: 1991-09-03
•
Expires: 2008-10-27
Abstract
Abstract Growth hormone is conjugated to any ligand, preferably a protein such as bovine serum albumin, optionally by use of a cross-linking agent such as a carbodiimide. The conjugates have enhanced activity when compared with unmodified growth hormone, and also better aqueous solubility at acid pH's.
Inventors
- 👤 Roger Aston
- 👤 Robert Bomford
- 👤 Andrew T. Holder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 17:05
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/27; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/642; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6813
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
51 words
A method of increasing growth hormone regulated response in a vertebrate which comprises administering to said vertibrate, a composition comprising an effective growth causing or enhancing an amount of non-immunogenic pharmaceutically acceptable, growth stimulating conjugated compound of growth hormone linked to a ligand which is selected from serum albumin or immunoglobulin.
Claim 2
Independent Claim
51 words
A method of increasing growth hormone regulated response in a vertebrate which comprises administering to said vertibrate, a composition comprising an effective growth causing or enhancing an amount of non-immunogenic pharmaceutically acceptable, growth stimulating conjugated compound of growth hormone linked to a ligand which is selected from serum albumin or immunoglobulin.
Claim 3
Dependent Claim
13 words
The method of claim 1, in which the ligand is bovine serum albumin.
Claim 4
Dependent Claim
13 words
The method of claim 2, in which the vertebrate is a dwarf child.
Claim 5
Independent Claim
66 words
A method of increasing growth hormone regulated response in a vertebrate which comprises administering to said vertibrate a composition comprising an effective growth causing or enhancing an amount of a non-immunogenic pharmaceutically growth stimulating conjugated compound of growth hormone linked to a ligand which is selected from serum albumin or immunoglobulin, and wherein said growth hormone is linked to said ligand by a cross linking agent.
Claim 6
Independent Claim
66 words
A method of increasing growth hormone regulated response in a vertebrate which comprises administering to said vertibrate a composition comprising an effective growth causing or enhancing an amount of a non-immunogenic pharmaceutically growth stimulating conjugated compound of growth hormone linked to a ligand which is selected from serum albumin or immunoglobulin, and wherein said growth hormone is linked to said ligand by a cross linking agent.
Claim 7
Dependent Claim
23 words
The method of claim 4 in which said cross linking agent is carbodiimide, glutaraldehyde, acid chloride, mixed anhidride, acylimidazale, or N-hydroxy succimmide ester.
Claim 8
Dependent Claim
21 words
The method of claim 4 in which the cross-linking agent or ligand binds to an amine group of the growth hormone.
Claim 9
Dependent Claim
13 words
The method of claim 4 in which the cross linking agent is glutaraldehyde.
Claim 10
Dependent Claim
13 words
The method of claim 4 in which the cross linking agent is carbodiimide.
Claim 11
Independent Claim
52 words
A method of increasing growth hormone regulated response in a dwarf child, which comprises administering to said dwarf child, a composition comprising an effective growth causing or enhancing amount of non-immunogenic pharmaceutically acceptable, growth stimulating conjugated compound of growth hormone linked to a ligand which is selected from serum albumin or immunoglobulin.
Claim 12
Independent Claim
52 words
A method of increasing growth hormone regulated response in a dwarf child, which comprises administering to said dwarf child, a composition comprising an effective growth causing or enhancing amount of non-immunogenic pharmaceutically acceptable, growth stimulating conjugated compound of growth hormone linked to a ligand which is selected from serum albumin or immunoglobulin.
References Cited (Backward Citations)
US3645852A
Cited
US4003792A
Cited
US4464468A
Cited
US4302386A
Cited
GB2115281A
Cited
EP0119650A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-02 | 1995-03-04 | 1995-09-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-02 | 1999-03-04 | 1999-09-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-02 | 2003-03-04 | 2003-09-03 | $7700.00 | Window Closed / Lapsed |